Cassava Sciences Inc (SAVA)
25.92
-0.29
(-1.11%)
USD |
NASDAQ |
Nov 04, 12:58
Cassava Sciences Enterprise Value: 1.050B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 1.050B |
| October 31, 2024 | 1.031B |
| October 30, 2024 | 1.040B |
| October 29, 2024 | 1.065B |
| October 28, 2024 | 1.075B |
| October 25, 2024 | 1.066B |
| October 24, 2024 | 1.102B |
| October 23, 2024 | 1.136B |
| October 22, 2024 | 1.157B |
| October 21, 2024 | 1.178B |
| October 18, 2024 | 1.184B |
| October 17, 2024 | 1.212B |
| October 16, 2024 | 1.214B |
| October 15, 2024 | 1.149B |
| October 14, 2024 | 1.112B |
| October 11, 2024 | 1.030B |
| October 10, 2024 | 985.40M |
| October 09, 2024 | 992.11M |
| October 08, 2024 | 1.042B |
| October 07, 2024 | 1.012B |
| October 04, 2024 | 1.092B |
| October 03, 2024 | 1.086B |
| October 02, 2024 | 1.085B |
| October 01, 2024 | 1.108B |
| September 30, 2024 | 1.205B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.159B |
| September 26, 2024 | 1.322B |
| September 25, 2024 | 1.255B |
| September 24, 2024 | 1.212B |
| September 23, 2024 | 1.088B |
| September 20, 2024 | 1.221B |
| September 19, 2024 | 1.249B |
| September 18, 2024 | 1.247B |
| September 17, 2024 | 1.294B |
| September 16, 2024 | 1.152B |
| September 13, 2024 | 1.142B |
| September 12, 2024 | 1.148B |
| September 11, 2024 | 1.104B |
| September 10, 2024 | 1.088B |
| September 09, 2024 | 1.085B |
| September 06, 2024 | 1.084B |
| September 05, 2024 | 1.206B |
| September 04, 2024 | 1.217B |
| September 03, 2024 | 1.135B |
| August 30, 2024 | 1.170B |
| August 29, 2024 | 1.161B |
| August 28, 2024 | 1.074B |
| August 27, 2024 | 1.175B |
| August 26, 2024 | 1.220B |
| August 23, 2024 | 1.278B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.524M
Minimum
Nov 18 2019
5.135B
Maximum
Jul 28 2021
968.83M
Average
839.92M
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 151.89B |
| Eli Lilly and Co | 805.11B |
| Seelos Therapeutics Inc | 10.27M |
| Biomarin Pharmaceutical Inc | 12.36B |
| EyePoint Pharmaceuticals Inc | 365.18M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.155M |
| Total Expenses (Quarterly) | 61.40M |
| EPS Diluted (Quarterly) | 0.13 |
| Earnings Yield | -5.44% |
| Operating Earnings Yield | 2.77% |
| Normalized Earnings Yield | 18.36 |